Advances in alzheimer therapy:Understanding Pharmacological approaches to the disease

Current Alzheimer Research

Volumn 6, Issue 2, 2009, Pages 83-85

  Martínez, Ana ^a   Lahiri, Debomoy K ^b   Giacobini, Ezio ^c   Greig, Nigel H ^d  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PRESENILIN 1; PRESENILIN 2; RIVASTIGMINE;

ALZHEIMER DISEASE; DRUG EFFICACY; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INCIDENCE; MILD COGNITIVE IMPAIRMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TERMINAL DISEASE; TREATMENT OUTCOME; TREATMENT PLANNING;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS;

EID: 64549128224     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787602924     Document Type: Review

References (8)

1. Greig NH, Lahiri DK and Giacobini E. Editorial:advances in Alzheimer therapy:something old, something new, something borrowed, something blue. Curr Alzheimer Res 2(3):275-9 (2005).
2. Greig NH, Giacobini E and Lahiri DK. Advances in Alzheimer therapy:development of innovative new strategies. Curr Alzheimer Res 4(4):336-9 (2007).
3. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia:evidence review for a clinical practice guideline. Ann Intern Med 148(5):379-97 (2008).
4. National Institute for Health and Clinical Excellence:TA111 Alzheimer's disease-donepezil, galantamine, rivastigmine (review) and memantine:guidance (amended September 2007) (MS Word format)-62 page download:http://www.nice.orrg. uk/guidance/ index.jsp?action=download&o=36558 (checked:February 9, 2009).
5. Becker RE and Greig NH. Alzheimer's disease drug development in 2008 and beyond:problems and opportunities. Curr Alzheimer Res 5(4):346-57 (2008).
6. Becker RE and Greig NH. Alzheimer's disease drug development:old problems require new priorities. CNS Neurol Disord Drug Targets 7(6):499-511 (2008).
7. Becker RE, Greig NH. Neuropsychiatric clinical trials:should they accommodate real-world practices or set standards for clinical practices? J Clin Psychopharmacol 29(1):56-64 (2009).
8. Becker RE, Unni LK, Greig NH. Resurrecting clinical pharmacology as a context for Alzheimer disease drug development. Curr Alzheimer Res 6(1):79-81 (2009).